Regulus Therapeutics Announces Resignation of Board Member
Regulus Therapeutics Inc. (Nasdaq: RGLS) announced the resignation of Simos Simeonidis from its Board of Directors, effective December 6, 2022. His departure is attributed to his new role as co-CEO and co-CIO at Ally Bridge Group. The Board expressed gratitude for his leadership, noting his significant contributions to the company's strategic direction. Regulus specializes in developing innovative medicines targeting microRNAs and is advancing the clinical development of RGLS8429 for treating ADPKD. The company emphasized its commitment to long-term success despite the leadership change.
- Simos Simeonidis provided impactful leadership and insights during his tenure.
- Regulus is advancing clinical development of RGLS8429 targeting ADPKD, indicating progress in its pipeline.
- The loss of Simeonidis may create a gap in leadership experience on the Board.
SAN DIEGO, Dec. 12, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that Simos Simeonidis, Ph.D., member of the Board of Directors, has stepped down from the Board, due to the time requirements of his recent appointment as co-Chief Executive Officer and co-Chief Investment Officer at Ally Bridge Group. His resignation was effective December 6, 2022.
"On behalf of the Board and the whole team at Regulus, I would like to thank Simos for his impactful leadership during his tenure at Regulus," said Stelios Papadopoulos, Ph.D., Chairman of the Board of Directors of Regulus. "Since joining the Board, Simos, with his expertise in investment management and biomedical research, has provided the team with invaluable insights that have helped Regulus achieve milestones and position the company for long-term success."
"Simos has been a valuable member of our team and we have appreciated his experience, dedication and thoughtful guidance as a Board member," said Jay Hagan, President and Chief Executive Officer of Regulus Therapeutics. "We appreciate his service and commitment to Regulus and wish him all the best in his future endeavors."
"It has been my pleasure to work with the Regulus management team in advancing the clinical development of RGLS8429," said Dr. Simeonidis. "I look forward to seeing the company continue its progress and deliver on novel targeted microRNA-based therapies for the treatment of ADPKD."
About Regulus
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. Regulus maintains its corporate headquarters in San Diego, CA.
Forward-Looking Statements
Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the Company's RGLS8429 program, including the expected timing and future occurrence of other preclinical and clinical activities. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and in the endeavor of building a business around such drugs, and the risk additional toxicology data may be negative. In addition, while Regulus expects the COVID-19 pandemic to adversely affect its business operations and financial results, the extent of the impact on Regulus' ability to achieve its preclinical and clinical development objectives and the value of and market for its common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the U.S. and in other countries, and the effectiveness of actions taken globally to contain and treat the disease. These and other risks are described in additional detail in Regulus' filings with the Securities and Exchange Commission, including under the "Risk Factors" heading of Regulus most recently quarterly report on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
View original content to download multimedia:https://www.prnewswire.com/news-releases/regulus-therapeutics-announces-resignation-of-board-member-301699963.html
SOURCE Regulus Therapeutics Inc.
FAQ
What prompted Simos Simeonidis to resign from Regulus Therapeutics?
When did Simos Simeonidis's resignation from the Board take effect?
What impact might the resignation of Simos Simeonidis have on Regulus Therapeutics?
What is the focus of Regulus Therapeutics in its clinical development?
